S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Seagen Stock Forecast, Price & News

-5.51 (-4.14%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.22 million shs
Average Volume
857,080 shs
Market Capitalization
$23.32 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Seagen logo

About Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.


2 Stock Sectors to Invest in for 2022 (SGEN)
January 5, 2022 |  marketbeat.com
Morgan Stanley Trims Seagen (NASDAQ:SGEN) Target Price to $178.00
January 18, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.18 billion
Cash Flow
$3.42 per share
Book Value
$19.28 per share


Net Income
$613.67 million
Pretax Margin




Free Float
Market Cap
$23.32 billion

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Social Links


Overall MarketRank

2.69 out of 5 stars

Medical Sector

65th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

11th out of 206 stocks

Analyst Opinion: 4.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

How has Seagen's stock been impacted by COVID-19?

Seagen's stock was trading at $104.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 22.0% and is now trading at $127.55.
View which stocks have been most impacted by COVID-19

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Seagen

How can I listen to Seagen's earnings call?

Seagen will be holding an earnings conference call on Wednesday, February 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) released its earnings results on Thursday, October, 28th. The biotechnology company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $1.05. The biotechnology company had revenue of $424.60 million for the quarter, compared to the consensus estimate of $384.83 million. Seagen had a negative net margin of 19.06% and a negative trailing twelve-month return on equity of 9.88%. The firm's quarterly revenue was down 60.0% on a year-over-year basis. During the same period last year, the company earned $3.50 EPS.
View Seagen's earnings history

What price target have analysts set for SGEN?

13 brokerages have issued twelve-month price targets for Seagen's shares. Their forecasts range from $145.00 to $254.00. On average, they anticipate Seagen's share price to reach $182.82 in the next twelve months. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by many different institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.01%), Gateway Investment Advisers LLC (0.01%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Snider Financial Group (0.01%) and Tributary Capital Management LLC (0.01%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen

Which institutional investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Tributary Capital Management LLC, State of Alaska Department of Revenue, IBM Retirement Fund, Kestra Advisory Services LLC, Russell Investments Group Ltd., Patriot Financial Group Insurance Agency LLC, and Elite Wealth Management Inc.. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which institutional investors are buying Seagen stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including Wealthfront Advisers LLC, Lattice Capital Management LLC, Sumitomo Mitsui DS Asset Management Company Ltd, Leavell Investment Management Inc., DNB Asset Management AS, Snider Financial Group, Whittier Trust Co., and Louisiana State Employees Retirement System.
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $127.55.

How much money does Seagen make?

Seagen has a market capitalization of $23.32 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,092 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

Where are Seagen's headquarters?

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.